| ［1］ |
Ko D, Choi S, Ha S, et al. The clinical severity score of chronic actinic dermatitis correlates with in vivo photoallergic reactions and the immunologic parameters related to a shift towards Th2 immunity from the Th2/Th1 balanced status in patients with chronic actinic dermatitis［J］. Photodermatol Photoimmunol Photomed, 2016,32（4）:199⁃206. DOI: 10.1111/phpp.12244.
|
| ［2］ |
中国研究型医院学会皮肤科学专业委员会, 中国医师协会皮肤科医师分会. 慢性光化性皮炎诊疗专家共识（2023版）［J］. 中华皮肤科杂志, 2023,56（12）:1096⁃1106. DOI: 10.35541/cjd. 20230433.
|
| ［3］ |
Liu W, Zhao Y, He Y, et al. Stapokibart （CM310） targets IL⁃4Rα for the treatment of type 2 inflammation［J］. iScience, 2024,27（9）:110721. DOI: 10.1016/j.isci.2024.110721.
|
| ［4］ |
Zhao Y, Zhou C, Man X, et al. Efficacy and safety of extending dosing interval of stapokibart in patients with atopic dermatitis［J］. Dermatitis, 2025:17103568251361896. DOI: 10.1177/1710 3568251361896.
|
| ［5］ |
陆毓, 郭奕妤, 秦建平, 等. 联合度普利尤单抗治疗慢性光化性皮炎1例［J］. 中华皮肤科杂志, 2024,57（2）:171⁃172. DOI: 10.35541/cjd.20210756.
|
| ［6］ |
Chen J, Yu N, Wu W, et al. The effectiveness and safety of dupilumab for the treatment of recalcitrant chronic actinic dermatitis: a case series［J］. Clin Cosmet Investig Dermatol, 2023,16:2357⁃2363. DOI: 10.2147/CCID.S422683.
|
